Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

That's because Greg, an engineer, rode his bike in the MS 150, a punishing ride, formerly between Houston and Austin. (The ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

The National Multiple Sclerosis society funds research, drives change through advocacy and provides programs and resources to help people affected by MS live their best ...

Background Previous natural history studies highlighted a consistent heterogeneity of disability trajectories among ...

The University of Oregon now has four confirmed international students who have had their visas revoked based on unspecified ...

A man with multiple sclerosis (MS) is about to undertake a feat of physical and mental endurance. Dominic Shadbolt, 53, from ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...